Abstract
Background
Resistance to antibiotics has increased steadily over time, thus there is a pressing need for safer alternatives to antibiotics. Current study aims to evaluate the influence of vitamin C as an antibacterial and anti-biofilm agent against uropathogenic E. coli (UPEC) strains. The expression of beta-lactamases and biofilm encoding genes among E. coli isolates before and after treating the isolates with sub MIC of vitamin C was analyzed by Real-time PCR. The in vivo assessment of the antibacterial and anti-biofilm effects of vitamin C against uropathogenic E. coli strains was done using a urinary tract infection (UTI) rat model.
Results
The effective concentration of vitamin C that could inhibit the growth of most study isolates (70%) was 1.25 mg/ml. Vitamin C showed a synergistic effect with most of the studied antibiotics; no antagonistic effect was detected at all. Vitamin C showed an excellent anti-biofilm effect against studied isolates, where 43 biofilm-producing isolates were converted to non-biofilm at a concentration of 0.312 mg/ml. The expression levels of most studied genes were down-regulated after treatment of E. coli isolates with vitamin C. In vivo assessment of vitamin C in treating UTIs showed that vitamin C has a rapid curative effect as the comparable antibiotic. Administration of both vitamin C and nitrofurantoin at a lower dose for treatment of UTI in rats had a better effect.
Conclusion
Vitamin C as an antibacterial and anti-biofilm agent either alone or in combination with antibiotics could markedly improve UTI in experimental rats.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12866-023-02856-3.
Keywords: E. coli, UTI, Vitamin C, Antibacterial, Anti-biofilm, Nitrofurantoin
Background
Antibiotic resistance is a major concern that is becoming a global problem worldwide due to the fast evolution of genetic exchange among bacterial species, so most potent antibiotics rapidly lose their efficacy. Biofilm is a group of microorganisms that attach to a surface forming a three-dimensional structure containing a protective polymeric matrix, which renders them highly resistant to antibiotics [1]. Some E. coli strains have been thought to employ the biofilm-forming abilities as a virulence factor to overcome the immune system and antimicrobial challenges [2]. Biofilm could also reduce antibiotic penetration into bacterial cells, give them a slower metabolic rate, and easier exchange of resistance genes among cells [3].
There is a pressing need for safer alternatives for antibiotics, particularly those that are natural, non-toxic, and do not cause resistance. Vitamin C (Ascorbic acid), a natural antioxidant component, is one such option that has no side effects, inexpensive, and is easily accessible [4]. Vitamin C is an essential water-soluble vitamin that cannot be synthesized by the body so it must be supplemented daily [5]. Vitamin C can be found in green peppers, red peppers, strawberries, tomatoes, broccoli, brussels sprouts, turnip, Indian gooseberry, and other leafy vegetables. However, animal sources are poor in vitamin C [6]. It is easily oxidized and damaged by oxygen and alkali; high temperature can also do this. It can be synthesized by most plant and animal species from glucose and galactose through the uronic acid pathway but humans and other primates cannot do so because of the lack of enzyme gluconolactone oxidase required for its biosynthesis [7]. The aim of this study is in vitro and in vivo evaluation of vitamin C as an antibacterial and anti-biofilm agent alone and in combination with antibiotics against uropathogenic E. coli strains, also to analyze the effect of vitamin C on the expression of certain antibiotic resistant genes and biofilm encoding genes of E. coli isolates.
Results
Antimicrobial susceptibility testing of antibiotics
The results of the susceptibility testing of all E. coli strains were categorized into sensitive, intermediate, and resistant strains according to CLSI breakpoints. The results were presented in Table 1. The most resistant phenotypes of our isolates were cefazolin, cefoxitin, and levofloxacin and the most sensitive phenotypes were meropenem and ampicillin-sulbactam.
Table 1.
Antibiotic | Total N = 100 (100%) | ||
---|---|---|---|
Resistant N (%) |
Intermediate N (%) |
Sensitive N (%) |
|
Meropenem | 20 (20%) | 31 (31%) | 49 (49%) |
Levofloxacin | 56 (56%) | 10(10%) | 34 (34%) |
Ceftazidime | 55 (55%) | 12 (12%) | 33 (33%) |
Nitrofurantoin | 53 (53%) | 9 (9%) | 38 (38%) |
Ampicillin-sulbactam | 42 (42%) | 14 (14%) | 44 (44) |
Cefazolin | 90 (90%) | 0 (0%) | 10 (10%) |
Cefoxitin | 88 (88%) | 4 (4%) | 8 (8%) |
Antibacterial effect of vitamin C
MIC of vitamin C against all study isolates was determined by the micro-dilution method. Out of 100 E. coli isolates, 15 isolates were inhibited by vitamin C at a concentration of 0.625 mg/ml, 70 isolates were inhibited by vitamin C at a concentration of 1.25 mg/ml and 15 isolates were inhibited by vitamin C at a concentration 2.5 mg/ml. The most effective concentration of vitamin C against most study isolates was 1.25 mg/ml as it can inhibit most E. coli isolates. There was no difference between MIC of vitamin C of antibiotic-sensitive or antibiotic-resistant strains.
The combined effect of vitamin C with antibiotics
The results of the combined effect of Vitamin C with antibiotics were summarized in Table 2. FIC calculation showed that vitamin C had a synergistic effect with most antibiotics (Levofloxacin, Meropenem, Ceftazidime and Nitrofurantoinm). Ampicillin/sulbactam, Cefazolin, and Cefoxitin showed an indifference effect when combined with vitamin C, no antagonistic effect was detected.
Table 2.
Antibiotic + vitamin C (A + B) |
FICA | FICB | FICI | Result |
---|---|---|---|---|
Meropenem + Vitamin C | 0.125 | 0.25 | 0.375 | Synergism |
Levofloxacin + Vitamin C | 0.125 | 0.25 | 0.375 | Synergism |
Ceftazidime + VItamin C | 0.25 | 0.25 | 0.5 | Synergism |
Nitrofurantoin + Vitamin C | 0.25 | 0.25 | 0.5 | Synergism |
Amp/Sulbactam + Vitamin C | 0.5 | 0.25 | 0.75 | Indifference |
Cefazolin + Vitamin C | 1 | 0.25 | 1.25 | Indifference |
Cefoxitin + Vitamin C | 1 | 0.25 | 1.25 | Indifference |
FICA FIC of antibiotic, FIC B FIC of vitamin C, FICI FIC index, The FIC index value ≤ 0.5 indicates synergy, > 0.5–4 indifference, and > 4 antagonism
Anti-biofilm effect of vitamin C
All E. coli isolates were tested for biofilm formation before and after in vitro treatment with vitamin C at different concentrations. Out of 100 uropathogenic E. coli isolates, 74 isolates were recorded as biofilm produced by the MTP method. Vitamin C had an anti-biofilm effect on study isolates. The biofilm inhibitory concentration (BIC) of each isolate was determined. The most effective concentration of vitamin C against most biofilm-producing isolates was 0.312 mg/ml (Supplementary Fig. S1) where 43 biofilm-producing isolates were converted to non-biofilm at this concentration, 24 isolates were converted to non-biofilm at a concentration of 0.625 mg/ml, and 7 isolates were converted to non-biofilm at a concentration of 1.25 mg/ml of vitamin C.
Determination of MIC50 and MIC90, BIC50, and BIC90 of the isolates
MIC50 and MIC90 values as well as the range of values obtained are important parameters for reporting results of susceptibility testing when multiple isolates of a given species are tested. The MIC50 represents the MIC value at which 50% of the isolates in a test population are inhibited. The MIC90 represents the MIC value at which 90% of the strains within a test population are inhibited. MIC90 was a concentration of 2.5 mg/ml of vitamin C and MIC50 was a concentration of 1.25 mg/ml of vitamin C. On the other hand, BIC90was a concentration of 0.625 mg/ml of vitamin C, and BIC 50 was a concentration of 0.312 mg/ml.
Time kill-kinetics assay
The time-kill kinetics study of the 2 MIC of vitamin C against the tested E. coli isolates significantly reduced the number of viable bacterial cells over the first 20 and 24 h, respectively. Moreover, the double MIIC of vitamin C significantly reduced the number of viable bacterial cells over the first 12, 16, 20, and 24 C(P value <0.05) as shown in Fig. 1.
Effect of vitamin C on the expression of antibiotic resistant genes and biofilm encoding genes
Real-time PCR was used for assessing the effect of vitamin C on the expression level of beta-lactamases encoding genes (blaSHV, blaTEM,, blaCTX-M, blaVIM,,blaNDM, and blaIMP) and biofilm-associated genes (lasR, lecA and pelA), respectively before and after vitamin C treatment. The median and the interquartile range (IQR) of the expression level for the studied genes before and after vitamin C treatment were presented in Table 3. The expression levels of all studied genes were decreased after treatment of E. coli isolates with vitamin C. Vitamin C significantly down regulated the expression level of the following genes: blaSHV, blaTEM, blaCTX-M,, blaNDM, blaIMP, lasR, and lecA (P value: 0.005, 0.003, 0.012, 0.007, 0.005, 0.028, and 0.013 respectively). However, the reduction in the expression level of blaVIM and pelA genes after treating E. coli isolates with vitamin C was statistically not significant (P value: 0.059 and 0.333 respectively).
Table 3.
Gene |
Before vitamin C treatment Median (IQR) |
After vitamin C treatment Median (IQR) |
P-value |
---|---|---|---|
blaSHV | 986.8 (699.1–12,284.4) | 259.5 (85.6–877.7) | 0.005* |
blaTEM | 127.5 (101.1–183.1) | 20.7 (11.5–68.6) | 0.003* |
blaCTX-M | 115.9 (82.7–191.6) | 32.7 (11.2–64.1) | 0.012* |
BlaVIM | 1107.4 (814.8–2269.4) | 1023.3 (755–1813.1) | 0.059 |
blaNDM | 70.1 (48.2–125.1) | 14.4 (5.7–30.2) | 0.007* |
blaIMP | 100.8 (80.4–207) | 9.4 (3.8–24.3) | 0.005* |
LasR | 1377.6 (269.1–5762.5) | 359.4 (170.4–575.7) | 0.028* |
LecA | 3381.3 (1395.8–8169.8) | 202.7 (87–2514.9) | 0.013* |
PelA | 4480.9 (398–6655.8) | 2283.8 (849.7–4755.2) | 0.333 |
-Wilcoxon Signed Rank test was used for comparison of non-parametric quantitative data between the two times, *: Significant level at P- value < 0.05
In vivo assessment of the antibacterial effect of vitamin C
Bacterial count
In our study urine samples from rat receiving vitamin C alone or in combination were highly acidic (PH = 4–5), the group receiving nitrofurantoin alone were also acidic but lower than that receiving vitamin C (PH = 6–7) and urine samples of infected not treated groups were mostly neutral (PH = 7).
The bacteria were counted in the urine at day zero and then daily after the start of treatment in all treatment groups and the positive control (UTI) group. There was a significant reduction of bacterial counts in urine in all treatment groups in comparison with the control group (P value <0.05) started from the first day after treatment and thereafter as shown in Fig. 2. Five days after treatment, the reduction of bacterial counts in urine was more pronounced in all treated groups. Two days after treatment and at the end of the experiment we examined the bacterial count in the urinary bladder and kidney of all groups. We found a significantly higher average CFU of bladder and kidney in rats of the UTI group than in rats of all treated groups as shown in Fig. 3. Five days after treatment, Kidney and urinary bladder returned sterile for all treatment groups.
Evaluation of oxidative stress parameters (MDA, GSH, TAC) and NFkB
Our data revealed that the UTI group showed significant increases in MDA, and NFkB but significant decreases in GSH, and TAC compared to the control group. However, UTI + N, UTI + C, and UTI + N + C showed significant decreases in MDA, and NFKB but increases in GSH, and TAC compared to the UTI group as shown in Fig. 4.
Histological examination
A comparison of the histological picture of rat kidney and urinary bladder of different groups was presented in figs. 5 and 6 respectively. Significant differences were found in kidney histopathology between the UTI group and the other treated groups. The kidneys of rats in the UTI group, killed 4 days after E. coli inoculation revealed severe signs of inflammation. In all treated rats (killed 2 days after treatment), either by antibiotic, vitamin c, or both, there was significant improvement of the histological picture and a significant reduction in the inflammatory infiltrates.
Discussion
In this study, E. coli isolates showeda higherresistant rate to cefazolin (90%), levofloxacin (56%), Ceftazidime (55%), Nitrofurantoin(53%), and ampicillin-sulbactam (42%). These results were in compatible with other previous studies [8–11].
The higher antibiotic resistance observed in this study may be due to emergence of resistant strains and excessive unwanted use of antibiotics so we recommended continuous follow of antibiotic resistance to catch the new resistant strains, requesting un needed antibiotics should be avoided and antibiotic susceptibility before antibiotics prescription should be done.
Although carbapenems were thought to be the best treatment for MDR E. coli infections, resistance to carbapenems is spreading due to the acquisition of β-lactamase, and carbapenemase [12]. Meropenem resistance in the present study was 20% among all E. coli isolates. Abd El-Baky et al. observed that E. coli in Egypt showed a 13% resistance rate to meropenem [13].
New multidrug-resistant bacteria strains are constantly developing. So, alternative therapeutic modalities that can aid in the control of the antibiotic resistance pandemic must be investigated, one such possibility is vitamin C [14].
Vitamin C's antibacterial effect is influenced by bacterial strain and concentration. The antibacterial properties of vitamin C may be due to its acidic PH. The plasma level of Vitamin C is influenced by daily consumption. Higher doses (> 100 mg/day) raise the plasma vitamin C levels and then eliminated almost entirely in the urine [15]. Urine excretion of vitamin C is significantly higher in persons taking a 2000 mg dosage when compared to 100 mg of vitamin C per day [16]. So, vitamin C provided considerable protection against uropathogenic adhesion and colonization of microbes that infect the urinary tract [17] through a high vitamin C consumption that tends to raise urine acidity, which is not well tolerated by the bacteria that cause UTIs [18]. Vitamin C is a reducing agent capable of rapidly eliminating reactive oxygen species (ROS), it also works as a pro-oxidant antibacterial molecule, potentially altering the antimicrobial efficacy of some antibiotics by two proposed mechanisms: I- the transfer of vitamin C into bacterial cells, which results in the synthesis of H2O2 and, as a result, ROS; and II- The production of lactate and acetic acids from vitamin C. In addition, the interaction of vitamin C with catalytically active metal ions could contribute to oxidative damage [19].
In our study, it was found that vitamin C showed excellent antibacterial activity against E. coli isolates alone or in combination with antibiotics. Vitamin C MIC against E. coli isolates ranged from 0.625 mg/ml to 2.5 mg/ml with the most effective concentration of vitamin C against most isolates at 1.25 mg/ml, similar results were found by Mahmood and Abdullah in Egypt, who reported that MIC of vitamin C was 5 mg/ml against all coliform species [18]. Also, our results were confirmed by previous findings that reported that MIC of vitamin C against gram-negative bacteria ranged between 2- 16 mg/mL [14, 20, 21].
There is no correlation between the antibacterial effect of vitamin C and antibiotic resistance. There was no difference between the MIC of vitamin C and different categories of antibiotic susceptibility. Our results indicated that vitamin C had an inhibitory effect on most isolates regardless of their resistance to antibiotics, these results were also confirmed by El-Gebaly et al. in Egypt [22].
In the current study, vitamin C combined with antibiotics was used against all study isolates. The FIC of the combined drug was determined. We noticed that vitamin C had a synergistic effect with most of the studied antibiotics (Levofloxacin, Meropenem Ceftazidime and Nitrofurantoin). The synergistic effect of vitamin C was previously confirmed by Mahmood and Abdullah in Egypt, who reported synergism between vitamin C and ciprofloxacin against ciprofloxacin-resistant E. coli strains [18] and by Khameneh et al. who reported the synergistic effect of vitamin C with antituberculous drugs against mycobacterium [23]. Kwiecińska-Piróg et al., Cursino et al., Srividya and Lakshminarasaiah also reported the synergism of vitamin C with different antibiotics [24–26].
In our study, it was found that vitamin C had an anti-biofilm effect on E. coli isolates where 0.312 mg/ml was the mean concentration for its anti-biofilm effect, similar results were reported by Shivaprasad et al.who detect that vitamin C-treated bacterial culture showed a 5.8 folds reduction in EPS production in comparison to control without vitamin C [4, 23].
By analyzing RNA from E. coli isolates before and after treatment with vitamin C, the current study determined the expression levels of beta-lactamases and biofilm encoding genes. The expression levels of most of the studied genes (blaSHV, blaTEM,,blaCTX-M,, blaNDM,, blaIMP, lasR, and lecA) were significantly reduced after vitamin C treatment(P values ˂0.05). Shivaprasad et al. reported the same results where expression levels of all the tested genes needed for E. coli biofilm formation were significantly down-regulated after vitamin C treatment [4].
Vitamin C shows acceptable in vitro results as an antibacterial and anti-biofilm agent, this encouraged us to test its effect in vivo. This is the first study wherein we evaluated the in vitro and in vivo effect of vitamin C as an antibacterial and anti-biofilm agent against E. coli clinical isolates.
In our in vivo experiment, the efficacy of vitamin C treatment in rats after a UTI with E. coli showed that: administration of vitamin C alone or combined with antibiotics in the infected animal improved the inflammation and lowered the bacterial count. Moreover our data revealed that vitamin C has a synergistic effect with antibiotics as administration of both vitamin C and nitrofurantoin at lower doses produces a more powerful effect. Also our data confirmed the anti-inflammatory and antioxidant properties of vitamin c as the UTI + C, and UTI + N + C groups showed significant decreases in the inflammatory mediators (MDA, and NFkB) but increases in antioxidants (GSH, and TAC) compared to the UTI group. Abdelraheem et al. confirmed these results and reported that vitamin C had a significant improvement effect as an antibacterial and anti-inflammatory agent in treatment of pneumonia caused by P. aeruginosa in rats [27].
Conclusion
Vitamin C shows good results as an antibacterial and anti-biofilm agent in vitro and in vivo alone or combined with antibiotics. Vitamin C should be routinely prescribed alone or with antibiotics as antibiotic modifier to treat UTI infections in clinical settings as this combination will shorten the antibiotic course and lower the antibiotic dose. We recommended further in vitro and in vivo studies to explore vitamin C's potential as a safe and effective antibacterial agent in the fight against rising antimicrobial resistance as there are only a few studies on vitamin C compound toxicity. As well as a large-scale investigation on a large number of E. coli clinical isolates and other E. coli genes are recommended to investigate the effect of vitamin C on biofilm formation and antibiotic resistance.
Methods
Bacterial strains
The study was carried out on 100 non-repeated clinical isolates of E. coli obtained from patients with urinary tract infection at Minia University Hospital. Identification of E. coli isolates was performed by colony morphology on MacConkey and XLD agar (Oxoid, England), Gram staining, and standard biochemical tests (Oxoid, England) that is: triple sugar iron, sugar fermentation, indole, methyl red, vogues proskauer, citrate and motility tests, according to Cheesbrough methods and interpretations [28].
Antimicrobial susceptibility testing of antibiotics and vitamin C
Antimicrobial susceptibility testing and MIC of antibiotics and vitamin C against all isolates were determined by the micro-dilution method. The selection of antibiotics and interpretation of results was done according to CLSI, 2020 guidelines [29]. The following antibiotics were chosen: Ampicillin-sulbactam, Cefazolin, Cefoxitin, Ceftazidime, Meropenem, Levofloxacin, and Nitrofurantoin.
Stock solutions of antibiotics were prepared by dissolving pharmaceutically purchased antibiotics (PHARCO B International, Egypt) in sterile distilled water (1 mg/ml). The stock solution of ascorbic acid was prepared by dissolving commercially purchased vitamin C (L-Ascorbic acid, Sigma) in sterile distilled water (10 mg/ml). The range of the twofold serial dilutions was made for each antibiotic below and above the sensitivity breakpoints according to CLSI, 2020 guidelines. The twofold serial dilutions of vitamin C were between 5 to 0.019 mg/ml.
Two-fold serial dilutions of antibiotics or vitamin C were prepared in a 100 μl volume of Mueller–Hinton broth (MHB) in the MTP wells from well 1 to well 9, so there were 9 folds serial dilutions of each antibiotic or vitamin C. 10 μl of bacterial suspension, diluted according to CLSI protocol (105 CFU/ml) was then inoculated in the wells. Wells containing an identical amount of basal medium with (positive control) and without (negative control) bacterial suspension, but free of antibiotics, and wells separately containing the antibiotic or vitamin C (drug control) were included in each assay as growth controls. The plates were incubated in an aerobic incubator for 20 h at 37 °C. MIC was visually determined and interpreted according to CLSI, 2020 guidelines. The MIC was defined as the minimal concentration of an antimicrobial that visually inhibited the bacterial growth after 20 h of incubation and was reported by observing the visual turbidity of the wells [30].
Time kill-kinetics assay
Bactericidal activity is defined as a higher than 3 log10 fold decrease in colony forming unit (99.9 killing of the starting inoculum). The time-kill assay can monitor the effect of various concentrations of antimicrobial agents over time concerning the different stages of bacterial growth. The time-kill kinetics of vitamin C was done according to CLSI guidelines. Briefly, a grown culture of Muller Hinton broth with pure bacterial colonies (1.0 × 106 CFU/mL) was inoculated with ascorbic acid at MIC and double MIC. Serial dilutions were done at each time point (0, 4, 8, 12, 16, 20, and 24 h) and subcultures on Muller Hinton agar plates were incubated at 37 ºC. A positive control was performed for the tested strains without vitamin C. A graph of log CFU versus time was created [31].
Assessment of the combined effect of vitamin C with antibiotics:
The effect of the combination of vitamin C and antibiotics on the resistant strains of the corresponding antibiotic was assessed by the micro-dilution method. Briefly, two-fold serial dilutions of antibiotics were prepared in 100 μl volume of MHB in MTP wells. Half the original MIC of vitamin C in 100 ul volume distilled water was added to all wells of the MTP, so the final concentration of vitamin C in all wells was 1̸4 the original MIC. The procedure was completed as mentioned above. MIC of combined agents was determined and compared with the MIC of antibiotics alone.
Fractional inhibitory concentration index (FICI) analysis: FICI was used to calculate synergism, indifference, or antagonism between two compounds according to the following equation:
"CA" refers to the MIC value of drug A in combination with drug B, where "MICA" refers to the MIC of drug A alone. "CB" refers to the MIC value of drug B in combination with drug A, where "MICB" refers to the MIC of drug B alone. The FIC index value ≤ 0.5 indicates synergy, > 0.5–4 indifference, and > 4 antagonism [32].
Anti-biofilm effect of vitamin C
All E. coli isolates were tested for biofilm formation before and after treatment with the sub MIC of vitamin C by the Micro-titre plate method for biofilm detection [26]. The MTP wells were inoculated with bacterial suspension (with 0.5McFarland turbidity) with and without serial dilutions of vitamin C. The MTP was incubated at 37 °C for 24 h. After incubation, the contents of the wells were decanted into a discard container and washed with saline then emptied by flicking the plate gently. The MTP was air dried at 60 °C for 60 min. The wells were stained with 150 μl of 0.2% crystal violet solution for 15 min. The stain was discarded and wells were washed with water. The stained wells were solubilized with 95% ethanol. The absorbance of each well was measured at 590 nm by an ELISA reader (model CS, Biotec).
Effect of vitamin C on gene expression
All beta-lactam resistant and biofilm-producing E. coli isolates were analyzed for the expression level of beta-lactamases encoding genes (blaSHV, blaTEM, blaCTX-M, blaVIM, blaNDM, and blaIMP) and biofilm-associated genes (lasR, lecA and pelA) respectively, before and after treating the isolates with vitamin C by relative gene expression method. It is a valuable method of quantifying gene expression by comparing target transcripts and reference genes. Relative gene expression calculations for the tested genes with rpsl gene as a reference gene were performed twice before and after in vitro treatment with vitamin C for all tested isolates by RT-PCR according to the following steps.
RNA extraction
All tested E. coli isolates were inoculated in nutrient broth. The turbidity of bacterial broth was adjusted to the turbidity of 0.5 McFarland standards. Two tubes for each isolate were prepared and sub MIC of vitamin C was added to one of them. All tubes were incubated for 24 h at 37 °C. After incubation, the tubes were centrifuged (13,000 rpm, 10 s) and the deposit has been used for RNA extraction according to the Direct-zol RNA extraction kit protocol (Zymo research CORP, Australia). The purity and concentration of the extracted RNA were evaluated by measuring the absorbance of the RNA using a spectrophotometer (Genova, USA). The quality of the extracted RNA was assessed via gel electrophoresis at 100 V.
Real-Time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) step
Real-Time PCR was performed on the extracted RNA using one-step Sybr green kits according to manufacture instructions (Sensi FAST SYBR Lo-ROX one-step Kit (code noBIO-74005). Each PCR reaction was prepared with a final volume of 20 μl (master mix: 10 μl, Forward primer: 0.8 μl, Reverse primer: 0.8 μl, Reverse transcriptase: 0.2 μl, RNase inhibitor, 0.4 μl, Water up to 16 μl and template: 4 μl). Each sample was tested out three times in three independent experiments and the average was taken Negative control samples containing deionized water were used with each run. The PCR conditions were adjusted according to the kit protocol as follows: reverse transcription for 10 min at 45 °C, Polymerase activation for 2 min at 95 °C, denaturation (40 cycles) for 5 s at 95 °C, and annealing/extension for 20 s at 60 °C. The PCR products were analyzed by gel electrophoresis, to exclude any unspecific products. The primer sequences used for amplification of the studied genes were taken from previous published studies [33, 34].
Interpretation of the results
The cycle threshold (CT) (the number of cycles required for the fluorescent signal to cross the threshold line in real-time PCR) was recorded for the target genes and reference gene to calculate the fold change (relative quantity “RQ”). The relative expression of target genes was calculated using the comparative cycle threshold (ΔΔCt) where, ΔCt = Ct (gene of interest)—Ct (reference gene) and ΔΔCt = ΔCT of the test sample –Δ CT of the control sample. RQ = 2 − ΔΔCt [35].
In vivo assessment of the antibacterial effect of vitamin C
Rats
Male Wistar rats weighing 250–280 g were obtained from National Research Center (Giza, Egypt). The 30 rats were divided into five groups (6 rats each), group one (Nitrofurantoin, N), group two (vitamin C; C), group three (vitamin C + Nitrofurantoin, C + N), group four, (UTI) and group five is the normal control group (Con).
All rats in all groups except the normal control group were trans-urethrally inoculated with E. coli clinical isolate The UTI rat model was based on that of Hannan with some modifications. The rats were anesthetized with ketamine. Anesthetized rats were inoculated trans-urethral with the bacterial suspension by the intravenous gauge (0.8 mm) as a catheter. The tips were perfectly smooth so that they did not cause tissue injury during inoculation. The catheter was carefully pushed in horizontally until it reached the top of the bladder, and 0.1 mL of bacterial suspension was injected into the bladder using a tuberculin syringe with 10 μl gradations over 5 s to avoid vesicoureteral reflux. The catheter was removed immediately after inoculation. Forty-eight hours after inoculation, treatment has been started. Treatment options are given by oral route for groups: 1, 2, and 3 for 5 days. Group 1 was treated with nitrofurantoin antibiotic (100 mg/kg/day), Group 2 was treated with vitamin C (200 mg/kg/day) and Group 3 was treated with nitrofurantoin (50 mg/kg/day) and vitamin C (100 mg/kg/day) for 5 days. Group 4 didn't receive any treatment [36].
Sample collections
Urine samples were collected in a sterile Eppendorf tube before bacterial inoculation (day zero) and then daily during the study period. At first we determined the PH of urine samples using commercial urine strips, and then bacterial count was done. Two rats from each group were culled 2 days after treatment (four days after inoculation) then the remaining rats were culled 5 days after treatment. Blood samples were collected from the abdominal aorta for serum separation. The kidneys and bladders were aseptically removed and used for bacteriological, biochemical, and histological examination.
Bacterial count
The kidney and bladder were aseptically homogenized in sterile saline using tissue homogenizers. 100 μl volumes of tenfold serial dilutions of the tissue homogenate and urine were cultured on solid media. The bacterial count was calculated per 1 ml of urine or per gram of tissue.
Evaluation of oxidative stress parameters (MDA, GSH, TAC) and NFkB
The most reliable index of lipid peroxidation is Malondialdehyde (MDA). It was measured according to Buege's method. In addition, measurement of reduced glutathione (GSH) was determined calorimetrically on basis that Ellman’s reagent could reduce the thiol group of GSH and yellow color is formed and detected by spectrophotometer at 412 nm.
The serum levels of TAC and tissue level of NFk B were quantified according to the manufacturer's instructions [37, 38].
Statistical analysis
Statistical analysis for the in vitro test was done by SPSS package version 23.0 (SPSS Inc., Chicago, IL, USA). Chi-squared tests were performed for categorical data; while Wilcoxon Signed Rank tests were performed for the comparison of continuous data. Statistical analyses for the in vivo results were performed using the Graph Pad Prism Version 9.0 (Graph Pad Software Inc. San Diego, CA, USA). Data are presented as means ± SEM unless otherwise specified. Differences in quantitative measures were assessed by Student’s t-test or one-way ANOVA followed by Turkey's multiple comparison tests, when appropriate. Differences were considered significant when the P value < 0.05.
Supplementary Information
Acknowledgements
We would like to thank the technicians at pharmacology department, Faculty of Medicine, Minia University, who helped us deal with mice.
Authors’ contributions
WKM, NAH and WMA conceived and designed the study. EMR, MMR, RKY and WMA performed the experiment and presented the results. The manuscript was written and revised by all authors. The author(s) read and approved the final manuscript.
Funding
Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).
Availability of data and materials
All data generated or analyzed during this study are included in this article.
Declarations
Ethics approval and consent to participate
Written informed consent was obtained from all participants. All methods were carried out in accordance to relevant guidelines and regulations. The human study has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for studies involving humans. The animal experiment was conducted according to ARRIVE ethical guidelines. All The study was approved by the research ethical committee of Faculty of Medicine, Minia University (Approval No. 267).
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322–332. doi: 10.1016/j.ijantimicag.2009.12.011. [DOI] [PubMed] [Google Scholar]
- 2.Al Safadi R, Abu-Ali GS, Sloup RE, et al. Correlation between in vivo biofilm formation and virulence gene expression in Escherichia coli O104:H4. PLoS One. 2012;7(7):e41628. 10.1371/journal.pone.0041628. [DOI] [PMC free article] [PubMed]
- 3.Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol. 2002;292(2):107-13. 10.1078/1438-4221-00196 [DOI] [PubMed]
- 4.Shivaprasad DP, Taneja NK, Lakra A, Sachdev D. In vitro and in situ abrogation of biofilm formation in E. coli by vitamin C through ROS generation, disruption of quorum sensing and exopolysaccharide production. Food Chem. 2021;341(Pt 1):128171. 10.1016/j.foodchem.2020.128171. [DOI] [PubMed]
- 5.Yigit US, Lambrecht FY, Unak P, Biber FZ, Medine EI, Cetinkaya B. Preparation of (99m)Tc labeled vitamin C (ascorbic acid) and biodistribution in rats. Chem Pharm Bull (Tokyo). 2006;54(1):1-3. 10.1248/cpb.54.1. [DOI] [PubMed]
- 6.Malo C, Wilson JX. Glucose modulates vitamin C transport in adult human small intestinal brush border membrane vesicles. J Nutr. 2000;130(1):63-9. 10.1093/jn/130.1.63. [DOI] [PubMed]
- 7.Chambial S, Dwivedi S, Shukla KK, John PJ, Sharma P. Vitamin C in disease prevention and cure: an overview. Indian J Clin Biochem. 2013;28(4):314-28. 10.1007/s12291-013-0375-3. [DOI] [PMC free article] [PubMed]
- 8.Parajuli NP, Maharjan P, Parajuli H, et al. High rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of ESBL producers from Nepal. Antimicrob Resist Infect Control. 2017;6:9. 10.1186/s13756-016-0168-6. [DOI] [PMC free article] [PubMed]
- 9.Mahmoud AT, Salim MT, Ibrahem RA, Gabr A, Halby HM. Multiple Drug Resistance Patterns in Various Phylogenetic Groups of Hospital-Acquired Uropathogenic E. coli Isolated from Cancer Patients. Antibiotics (Basel). 2020;9(3):108. 10.3390/antibiotics9030108. [DOI] [PMC free article] [PubMed]
- 10.Khater ES. Association between virulen resistance in E. coli patients in Banha. 2021. [Google Scholar]
- 11.Loras C, Mendes AC, Peixe L, Novais Â, Alós JI. Escherichia coli resistant to fosfomycin from urinary tract infections: Detection of the fosA3 gene in Spain. J Glob Antimicrob Resist. 2020;21:414-6. 10.1016/j.jgar.2020.01.023. [DOI] [PubMed]
- 12.Gong L, Tang N, Chen D, et al. A Nosocomial Respiratory Infection Outbreak of Carbapenem-Resistant Escherichia coli ST131 With Multiple Transmissible blaKPC-2 Carrying Plasmids. Front Microbiol. 2020;11:2068. 10.3389/fmicb.2020.02068. [DOI] [PMC free article] [PubMed]
- 13.Abd El-Baky RM, Ibrahim RA, Mohamed DS, Ahmed EF, Hashem ZS. Prevalence of Virulence Genes and Their Association with Antimicrobial Resistance Among Pathogenic E. coli Isolated from Egyptian Patients with Different Clinical Infections. Infect Drug Resist. 2020;13:1221-1236. 10.2147/IDR.S241073. [DOI] [PMC free article] [PubMed]
- 14.Verghese RJ, Mathew SK, David A. Antimicrobial activity of Vitamin C demonstrated on uropathogenic Escherichia coli and Klebsiella pneumoniae. J Curr Res Sci Med. 2017;3:88-93.
- 15.Choi J, Kim DY, Choue R, Lim H. Effects of Vitamin C Supplementation on Plasma and Urinary Vitamin C Concentration in Korean Women. Clin Nutr Res. 2017;6(3):198-205. 10.7762/cnr.2017.6.3.198. [DOI] [PMC free article] [PubMed]
- 16.Shibata K, Fukuwatari T, Ohta M, et al. Values of water-soluble vitamins in blood and urine of Japanese young men and women consuming a semi-purified diet based on the Japanese Dietary Reference Intakes. J Nutr Sci Vitaminol (Tokyo). 2005;51(5):319-28. 10.3177/jnsv.51.319. [DOI] [PubMed]
- 17.Habash MB, Van der Mei HC, Busscher HJ, Reid G. The effect of water, ascorbic acid, and cranberry derived supplementation on human urine and uropathogen adhesion to silicone rubber. Can J Microbiol. 1999;45(8):691-4. 10.1139/w99-065. [DOI] [PubMed]
- 18.Mahmood MT, Abdullah BAJAotRSfCB. Antibacterial Activity of Ascorbic Acid (Vitamin C) Against Urinary Quinolones Resistant Coliform Species. Annals of R.S.C.B. 2021;25(5):1282-93.
- 19.Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions?. FASEB J. 1999;13(9):1007-1024. 10.1096/fasebj.13.9.1007. [DOI] [PubMed]
- 20.Zhang HM, Wakisaka N, Maeda O, Yamamoto T. Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: Helicobacter pylori. Cancer. 1997;80(10):1897-903. [PubMed]
- 21.Sendamangalam V. Antibiofouling effect of polyphenols on Streptococcus biofilms: University of Toledo. 2010. [Google Scholar]
- 22.El-Gebaly E, Essam T, Hashem S, El-Baky R. Effect of Levofloxacin and Vitamin C on Bacterial Adherence and Preformed Biofilm on Urethral Catheter Surfaces. J Microb Biochem Technol. 2012;04. 10.4172/1948-5948.1000083.
- 23.Khameneh B, Fazly Bazzaz BS, Amani A, Rostami J, Vahdati-Mashhadian N. Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains. Microb Pathog. 2016;93:83-87. 10.1016/j.micpath.2015.11.006. [DOI] [PubMed]
- 24.Cursino L, Chartone-Souza E, Nascimento A. Synergic interaction between ascorbic acid and antibiotics against Pseudomonas aeruginosa. Braz Arch Biol Technol. 2005;48:379-84. 10.1590/S1516-89132005000300007.
- 25.Srividya G, Deepthi B, Lakshminarasaiah S. Ascorbic acid enhances ciprofloxacin antibacterial activity in vitro against isolates of Escherichia coli from subclinical mastitis cases of buffaloes. Int J Vet Sci Anim Husbandry. 2017;2(5):21-4.
- 26.Kwiecińska-Piróg J, Skowron K, Bogiel T, Białucha A, Przekwas J, Gospodarek-Komkowska E. Vitamin C in the Presence of Sub-Inhibitory Concentration of Aminoglycosides and Fluoroquinolones Alters Proteus mirabilis Biofilm Inhibitory Rate. Antibiotics (Basel). 2019;8(3):116. 10.3390/antibiotics8030116. [DOI] [PMC free article] [PubMed]
- 27.Abdelraheem WM RM, Yousef RKM, Abd El Fatah AS. Mousa YM, Rashwan R. Assessment of Antibacterial and Anti-biofilm Effects of Vitamin C Against Pseudomonas aeruginosa Clinical Isolates. Front Microbiol. 2022;13:847449. doi: 10.3389/fmicb.2022.847449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Cheesbrough M. District laboratory practice in tropical countries, part 2. Cambridge university press , UK, Chapter (3), 63–70 45) Cheloni, G, Marti, E, and Slaveykova, V I (2016) Interactive effects of copper. (2006).
- 29.Clinical Laboratory Standards Institute (CLSI) M100. Wayne, PA: P.S.f., A.S.T.t.-f.i.S. 2020;37(1):90–92.
- 30.Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis. 2009;49(11):1749-55. 10.1086/647952. [DOI] [PubMed]
- 31.CLSI . MoDBAoAAAG, M26, V. 19, No. 18. 1999. [Google Scholar]
- 32.Mackay ML, Milne K, Gould IM. Comparison of methods for assessing synergic antibiotic interactions. Int J Antimicrob Agents. 2000;15(2):125–129. doi: 10.1016/S0924-8579(00)00149-7. [DOI] [PubMed] [Google Scholar]
- 33.Hassuna NA, Khairalla AS, Farahat EM, Hammad AM, Abdel-Fattah M. Molecular characterization of Extended-spectrum beta lactamase- producing E. coli recovered from community-acquired urinary tract infections in Upper Egypt. Sci Rep. 2020;10(1):2772. doi: 10.1038/s41598-020-59772-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Abdelraheem W, Abdelkader A, Mohamed E, Mohammed M. Detection of biofilm formation and assessment of biofilm genes expression in different Pseudomonas aeruginosa clinical isolates. Meta Gene. 2020;23:100646.
- 35.VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008;44(5):619-26. 10.2144/000112776. [DOI] [PubMed]
- 36.Hannan TJ. A Murine Model for Escherichia coli Urinary Tract Infection. Methods Mol Biol. 2016;1333:159–175. doi: 10.1007/978-1-4939-2854-5_14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Buege J, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302–310. doi: 10.1016/S0076-6879(78)52032-6. [DOI] [PubMed] [Google Scholar]
- 38.Beutler E. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882–888. [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data generated or analyzed during this study are included in this article.